Reported resultsCompany-reported
What was reported
EDEN PRAIRIE, Minn., August 13, 2026 -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results and provided a business update for the third quarter of fiscal year 2026 ended June 30, 2026.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 13, 2026 · Open the source ↗
What the evidence supports
NeuroOne Medical published its results for the period in a press release furnished to the SEC (Form 8-K, Item 2.02).
What remains unknown
Audit status of the figures (results furnished on Form 8-K or 6-K are typically unaudited), and anything about future periods. Any outlook is the company's own projection. Figures and claims are the company's own description and have not been independently verified.
Figures as stated
Numbers exactly as written in the source. We don’t annualise, convert or add them up.
| Figure | In context |
|---|---|
| $2.0 million | “● Product revenue increased 16% to $2.0 million, compared to $1.7 million in the same year-ago period.” Mentions: revenue |
| $1.7 million | “● Product revenue increased 16% to $2.0 million, compared to $1.7 million in the same year-ago period.” Mentions: revenue |
| $2.7 million | “● The Company received $2.7 million of new product orders to ship during the quarter, representing 43% growth in product orders year over year.” |
| $11.2 million | “● The Company has received product orders of $11.2 million for fiscal year 2026.” |
| $9.2 million | “Recognized revenue is expected to range from $9.2 million to $10.5 million depending primarily on manufacturing completion and timing of shipments, with any unshipped orders contributing to backlog.” Mentions: revenue, backlog |
| $10.5 million | “Recognized revenue is expected to range from $9.2 million to $10.5 million depending primarily on manufacturing completion and timing of shipments, with any unshipped orders contributing to backlog.” Mentions: revenue, backlog |
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Press release headlineNeuroOne® Reports Fiscal Q3 2026 Financial Results, Revenues Increase 16% YoY to $2.0 Million; Gross Margins Expand to 59.9%U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 13, 2026 · Open the source ↗
Press release lead paragraphEDEN PRAIRIE, Minn., August 13, 2026 -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results and provided a business update for the third quarter of fiscal year 2026 ended June 30, 2026.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 13, 2026 · Open the source ↗
Amount stated in press release● Product revenue increased 16% to $2.0 million, compared to $1.7 million in the same year-ago period.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 13, 2026 · Open the source ↗
Amount stated in press release● The Company received $2.7 million of new product orders to ship during the quarter, representing 43% growth in product orders year over year.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 13, 2026 · Open the source ↗
Amount stated in press release● The Company has received product orders of $11.2 million for fiscal year 2026.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 13, 2026 · Open the source ↗
Amount stated in press releaseRecognized revenue is expected to range from $9.2 million to $10.5 million depending primarily on manufacturing completion and timing of shipments, with any unshipped orders contributing to backlog.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 13, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:53 UTC
NeuroOne® Reports Fiscal Q3 2026 Financial Results, Revenues Increase 16% YoY to $2.0 Million; Gross Margins Expand to 59.9%
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.